Health Professionals

iOnctura commences randomized Phase II study in metastatic uveal melanoma

GENEVA and AMSTERDAM, March 20, 2025 /PRNewswire/ — iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the first patient in the randomized Phase II OCULE-01 study investigating lead asset roginolisib in patients with metastatic uveal melanoma (UM), a rare cancer of the eye.

Read More
MRV News
Melanoma News
Archive
Menu